Wedbush Forecasts Ardelyx’s FY2025 Earnings (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX) – Analysts at Wedbush decreased their FY2025 earnings per share (EPS) estimates for shares of Ardelyx in a report issued on Wednesday, April 16th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will earn ($0.26) per share for the year, down from their previous estimate of ($0.25). The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx’s Q1 2026 earnings at ($0.03) EPS.

Several other equities analysts also recently commented on ARDX. Cantor Fitzgerald raised shares of Ardelyx to a “strong-buy” rating in a research note on Tuesday, March 4th. LADENBURG THALM/SH SH reissued a “buy” rating and set a $11.00 price objective on shares of Ardelyx in a report on Friday, March 7th. Scotiabank assumed coverage on Ardelyx in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price for the company. Jefferies Financial Group cut their price target on Ardelyx from $11.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, January 2nd. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $5.50 price objective on shares of Ardelyx in a research note on Friday, February 21st. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.61.

Ardelyx Stock Up 4.8 %

ARDX stock opened at $4.82 on Friday. The firm has a 50-day moving average price of $5.13 and a 200-day moving average price of $5.34. Ardelyx has a 12 month low of $4.02 and a 12 month high of $9.33. The company has a current ratio of 4.58, a quick ratio of 4.31 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $1.15 billion, a P/E ratio of -30.13 and a beta of 0.81.

Ardelyx (NASDAQ:ARDX) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. Ardelyx had a negative return on equity of 24.87% and a negative net margin of 11.73%. The firm had revenue of $116.13 million for the quarter, compared to the consensus estimate of $111.16 million.

Hedge Funds Weigh In On Ardelyx

Institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC boosted its stake in Ardelyx by 13.3% during the fourth quarter. Janus Henderson Group PLC now owns 24,387,941 shares of the biopharmaceutical company’s stock worth $123,587,000 after acquiring an additional 2,858,061 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Ardelyx by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 14,362,659 shares of the biopharmaceutical company’s stock valued at $72,819,000 after buying an additional 767,111 shares during the period. Geode Capital Management LLC increased its position in Ardelyx by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 5,509,730 shares of the biopharmaceutical company’s stock valued at $27,941,000 after buying an additional 21,988 shares in the last quarter. Northern Trust Corp raised its stake in Ardelyx by 2.4% during the 4th quarter. Northern Trust Corp now owns 2,150,974 shares of the biopharmaceutical company’s stock worth $10,905,000 after buying an additional 50,441 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Ardelyx by 5.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,035,135 shares of the biopharmaceutical company’s stock worth $10,318,000 after acquiring an additional 96,357 shares in the last quarter. 58.92% of the stock is currently owned by institutional investors.

Insider Transactions at Ardelyx

In other news, Director David M. Mott purchased 199,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were acquired at an average price of $4.99 per share, with a total value of $993,010.00. Following the completion of the transaction, the director now owns 1,937,765 shares of the company’s stock, valued at $9,669,447.35. The trade was a 11.44 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laura A. Williams sold 4,941 shares of Ardelyx stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $5.62, for a total value of $27,768.42. Following the completion of the transaction, the insider now directly owns 303,804 shares of the company’s stock, valued at approximately $1,707,378.48. This trade represents a 1.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 158,076 shares of company stock worth $823,804 over the last three months. 5.90% of the stock is owned by company insiders.

About Ardelyx

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.